DEF: Aptose Biosciences Aims for AML Breakthrough with Tuspetinib; Seeks Shareholder Approval for Key Proposals

Aptose Biosciences focuses on advancing its tuspetinib-based triplet therapy for AML and seeks shareholder approval for a reverse stock split and stock incentive plan amendment at the upcoming annual meeting.

Summary

• Aptose Biosciences is prioritizing the development of tuspetinib (TUS) in combination with venetoclax (VEN) and azacitidine (AZA) as a frontline therapy for acute myeloid leukemia (AML).
• The company initiated the TUSCANY trial in 2024 to evaluate the TUS+VEN+AZA triplet in newly diagnosed AML patients.
• Tuspetinib has shown favorable safety and broad activity across AML genetic subtypes, potentially addressing 70% of AML cases.
• Aptose completed single-agent and doublet studies with tuspetinib in R/R AML during 2024, treating over 170 patients.
• The company entered a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to collaborate on clinical development of TUS.
• Aptose completed several financings in 2024, raising approximately $37 million to support the TUS-based triplet therapy development.
• Shareholders are being asked to approve an amendment to the 2021 stock incentive plan to increase the number of shares reserved by 458,126.
• Shareholders are also being asked to approve a reverse stock split at a ratio between 1-for-2 and 1-for-20.
• The annual and special meeting of shareholders will be held on May 27, 2025, as an online-only meeting.

Sentiment

Score: 7

Explanation: The document expresses optimism about the potential of tuspetinib and the company's progress in clinical development. However, the need for a reverse stock split and the change in auditors introduce some uncertainty.

Positives

• Tuspetinib demonstrates a favorable safety profile and broad activity across AML genetic subtypes.
• The TUS+VEN+AZA triplet therapy has achieved complete remissions (CRs) in difficult-to-treat AML patients.
• The CRADA with the NCI provides access to the NCI's clinical trials network.
• The company has secured approximately $37 million in financing to support clinical development.
• Key opinion leaders (KOLs) and potential pharma partners have expressed enthusiasm for tuspetinib's potential, estimating a $1Bn+ annual commercial impact in the frontline AML setting.

Negatives

• KPMG will not stand for re-appointment as the Corporations independent registered public accounting firm to serve as independent auditor for the Corporation's 2025 annual audit.
• The company is seeking shareholder approval for a reverse stock split, which can be perceived negatively by investors.
• The company was delisted from the Nasdaq Stock Market on April 2, 2025, for failing to maintain shareholders equity requirements.

Risks

• AML is a highly aggressive and heterogeneous cancer with a poor prognosis for elderly patients.
• Responses to salvage therapies in the relapsed or refractory (R/R) setting are limited.
• Current experimental agents added to VEN+HMA have toxicities and limited activity across AML subpopulations.
• The reverse stock split may not achieve the desired increase in share price or attract new investors.
• The company may not be able to complete the search for a successor auditor prior to the annual meeting.

Future Outlook

Aptose remains optimistic and believes it can navigate the challenges of biotechnology development to deliver tuspetinib as an important drug for AML patients and deliver value to investors.

Management Comments

• We believe that tuspetinib can have its greatest AML patient impact as a frontline triplet therapy by improving the response rates, the depth of responses, the durability of responses, the quality of life, and the long-term survival across a diversity of AML patients.
• The KOLs, potential partners, and our internal team all agree the TUS+VEN+HMA triplet regimen has the potential to become a mutation agnostic and new standard of care for frontline treatment of newly diagnosed AML.

Industry Context

The document positions tuspetinib as a potential improvement over existing AML therapies, which often suffer from toxicities and limited activity across AML subpopulations. The focus on a mutation-agnostic triplet therapy aligns with the industry's trend towards personalized medicine and combination therapies.

Comparison to Industry Standards

• The standard of care (SOC) therapy for newly diagnosed AML patients in the frontline setting includes a doublet combination of venetoclax and a hypomethylating agent (VEN+HMA), such as azacitidine.
• Current experimental agents added to VEN+HMA to create triplet therapies have achieved notable response rates but are inadequate because of toxicities, the inability to dose VEN and HMAs at the SOC levels, and the limited activity across subpopulations of AML patients.
• In contrast, tuspetinib is a convenient, orally administered, once daily kinase inhibitor with an excellent safety profile and broad activity across AML populations with adverse genetics.

Stakeholder Impact

• Shareholders: Potential for increased share value through successful drug development and strategic initiatives.
• Patients: Potential for improved treatment options and outcomes for AML.
• Employees: Continued employment and potential for equity-based compensation.
• Strategic Partners: Continued collaboration on clinical development and potential commercialization.

Next Steps

• Obtain shareholder approval for the amendment to the 2021 stock incentive plan.
• Obtain shareholder approval for the reverse stock split.
• Complete the search for a successor auditor.
• Continue clinical development of tuspetinib, including the TUSCANY trial.
• Collaborate with the NCI on clinical development of TUS through the CRADA.

Key Dates

Keywords

tuspetinib, AML, leukemia, Aptose, CRADA, triplet therapy, reverse stock split, financing, TUSCANY trial, venetoclax, azacitidine, hematologic malignancies